Analyst Ratings For AbbVie Inc (NYSE:ABBV)
Today, AbbVie Inc (NYSE:ABBV) stock received an upgrade by Leerink Swann from Market Perform to Outperform.
There are 9 Hold Ratings, 5 Buy Ratings, 2 Sell Ratings, no Strong Buy Ratings on the stock.
The current consensus rating on AbbVie Inc (NYSE:ABBV) is Hold with a consensus target price of $98.2308 per share, a potential 49.51% upside.
Some recent analyst ratings include
- 6/26/2019-AbbVie Inc (NYSE:ABBV) gets upgraded to Outperform by Leerink Swann
- 5/28/2019-AbbVie Inc (NYSE:ABBV) has coverage initiated with a Neutral ➝ Neutral rating and $84.00 price target
- 4/28/2019-AbbVie Inc (NYSE:ABBV) gets upgraded to Market Perform by BMO Capital Markets with a price target of $79.00
- 3/25/2019-AbbVie Inc (NYSE:ABBV) gets downgraded to Hold by Argus
- 2/14/2019-AbbVie Inc (NYSE:ABBV) had its Hold rating reiterated by Barclays with a $86.00 price target
- 1/23/2019-AbbVie Inc (NYSE:ABBV) had its Neutral ➝ Neutral rating reiterated by UBS Group with a $91.00 price target
- On 3/25/2019 Brian L Durkin, VP, sold 475 with an average share price of $79.69 per share and the total transaction amounting to $37,852.75.
- On 3/14/2019 Laura J Schumacher, Vice Chairman, sold 25,000 with an average share price of $80.00 per share and the total transaction amounting to $2,000,000.00.
- On 3/5/2019 Azita Saleki-Gerhardt, EVP, sold 15,797 with an average share price of $79.03 per share and the total transaction amounting to $1,248,436.91.
- On 12/28/2018 Laura J Schumacher, Vice Chairman, sold 25,000 with an average share price of $90.00 per share and the total transaction amounting to $2,250,000.00.
- On 12/28/2018 Laura J Schumacher, Vice Chairman, sold 25,000 with an average share price of $90.00 per share and the total transaction amounting to $2,250,000.00.
- On 12/12/2018 William J Chase, EVP, sold 60,000 with an average share price of $90.00 per share and the total transaction amounting to $5,400,000.00.
- On 12/11/2018 Richard A Gonzalez, Chairman, sold 16,850 with an average share price of $88.75 per share and the total transaction amounting to $1,495,437.50.
About AbbVie Inc (NYSE:ABBV)
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. Read More…
Recent Trading Activity for AbbVie Inc (NYSE:ABBV)
Shares of AbbVie Inc closed the previous trading session at 65.70 −12.71 16.21% with 70.47 shares trading hands.